vascuCAP vs Ligence Heart
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A (vascuCAP) specializes in AI-powered analysis of CT angiography for plaque quantification and cardiovascular risk stratification, providing insights for conditions like stroke and heart attack. In contrast, Tool B (Ligence Heart) automates the analysis and reporting of 2D transthoracic echocardiography, focusing on enhancing efficiency and accuracy for cardiologists and sonographers through automated measurements and disease recognition. While both are cardiology AI solutions, they cater to different diagnostic imaging modalities and offer distinct analytical focuses.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
vascuCAP (now ElucidVivo/PlaqueIQ) is designed for the analysis of non-invasive CT angiography. In contrast, Ligence Heart automates the analysis and reporting of 2D transthoracic echocardiography.
vascuCAP quantifies plaque composition, including lipid-rich necrotic core, calcification, non-calcified matrix, and intraplaque hemorrhage, to assess cardiovascular risk and support personalized treatment decisions. Ligence Heart provides automated view classification, heart phase prediction, calculation of various echocardiography measurements (Area, Distance, Doppler, Volume, strain), and disease recognition for conditions like heart failure and valvular heart diseases.
vascuCAP offers DICOM integration and PACS/EMR interoperability. Ligence Heart integrates with existing systems such as PACS, EHR, and RIS, and can transfer echocardiography images (with PHI removed) from hospital PACS.
vascuCAP provides risk stratification for stroke and heart attack based on its plaque assessment. Ligence Heart includes disease recognition capabilities for conditions such as heart failure, cardiomyopathy, pulmonary hypertension, and valvular heart diseases.
vascuCAP features histologically-validated plaque quantification and characterization. The provided information for Ligence Heart does not specify a particular validation method for its analytical accuracy.